Olinvacimab
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Triple-Negative Breast Cancer
Conditions
Metastatic Triple-Negative Breast Cancer
Trial Timeline
Sep 30, 2021 → Dec 3, 2024
NCT ID
NCT04986852About Olinvacimab
Olinvacimab is a phase 2 stage product being developed by Merck for Metastatic Triple-Negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04986852. Target conditions include Metastatic Triple-Negative Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Triple-Negative Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04986852 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Triple-Negative Breast Cancer